top of page
Search

CRISPR-Cas9: Experimental CTX310 therapy reduces triglycerides in a phase 1b clinical trial

5 hours ago
5 min read

An in vivo gene-editing strategy targeting the ANGPTL3 gene achieved an average 63% reduction in triglyceride levels after 30 days in adults with severe hypertriglyceridemia.


An experimental therapy based on CRISPR-Cas9 technology has shown early results in reducing triglyceride levels in adults with severe hypertriglyceridemia. The data were released on November 9, 2026, by CRISPR Therapeutics and concern CTX310, an in vivo gene-editing therapy targeting ANGPTL3, a gene involved in regulating lipid metabolism.


The results were presented in a Late-Breaking Science oral session at the American Heart Association (AHA) Scientific Sessions 2026. The study evaluated ten participants and showed average reductions of 65% in ANGPTL3 protein levels and 63% in triglycerides 30 days after treatment.



How Does the Gene-Editing Strategy Work?


CTX310 uses CRISPR-Cas9 technology to modify the ANGPTL3, gene, which encodes angiopoietin-like protein 3, also known as ANGPTL3. Produced primarily by the liver and released into the bloodstream, this protein helps regulate lipid metabolism.


ANGPTL3 inhibits enzymes involved in lipoprotein metabolism, particularly lipoprotein lipase (LPL) and endothelial lipase. LPL plays an important role in breaking down triglycerides carried by circulating lipoproteins, allowing fatty acids to be released for use by tissues.


Inhibiting ANGPTL3 activity may therefore enhance LPL activity and help reduce circulating triglyceride levels. CTX310 is designed to use gene editing to introduce a loss-of-function change in the ANGPTL3 gene, reducing the production or functional activity of the protein and thereby modifying this lipid-regulating mechanism.


To achieve this, the therapy uses lipid nanoparticles (LNPs) to deliver messenger RNA encoding the Cas9 enzyme and guide RNA, which directs the system to the specific location in the genome where editing is intended to occur.


Following intravenous administration, these components are delivered primarily to liver cells, where the target gene is edited. Unlike ex vivo strategies, in which cells are modified in a laboratory and subsequently reinfused into the patient, the in vivo approach allows gene-editing components to be administered directly into the body.


What Did the Phase 1b Clinical Trial Show?


The phase 1b study is multicenter and open-label, meaning that participants and researchers know which treatment is being administered. The cohort of adults with severe hypertriglyceridemia included ten participants with fasting triglyceride levels above 500 mg/dL.


Participants received a single intravenous infusion of CTX310. The administered dose was 40 mg for individuals weighing less than 85 kg and 50 mg for those weighing 85 kg or more. The cohort also included one participant previously treated in phase 1a who had received a dose of 56.5 mg.


All participants had diabetes, three had a history of pancreatitis, and two had clinical atherosclerotic cardiovascular disease. Median baseline triglyceride levels exceeded 1,000 mg/dL, reflecting a population with substantial disturbances in lipid metabolism.


Thirty days after administration, the following average reductions from baseline were observed:


  • 65% in circulating ANGPTL3 protein levels;

  • 63% in triglyceride levels;

  • 51% in non-HDL cholesterol;

  • 23% in apolipoprotein B (ApoB);

  • 16% in LDL cholesterol (LDL-C).


The reductions observed in non-HDL cholesterol and ApoB also indicate changes in other components associated with atherogenic lipoproteins, which contribute to the development of cardiovascular disease.


According to the company’s announcement, all ten participants had completed at least 30 days of follow-up by the data cutoff date. In addition, seven had completed at least 90 days, during which reductions in ANGPTL3 and triglycerides were sustained.


Safety and Tolerability: What Do We Know So Far?


Regarding safety, CRISPR Therapeutics reported that the treatment was well tolerated during the assessment period. No serious adverse events related to CTX310 or clinically meaningful elevations in the liver enzymes AST and ALT, which are monitored for potential changes in liver function, were reported.


One participant experienced a grade 2 infusion-related reaction that resolved, allowing the infusion to be completed. No treatment-related adverse events of grade 3 or higher were observed.


Another finding highlighted in the announcement was the absence of acute pancreatitis episodes during the study, although 30% of participants had a history of the condition.


These observations are relevant because severe hypertriglyceridemia is associated with a risk of acute pancreatitis, particularly when triglyceride levels are very high.


However, the safety data remain preliminary. The small number of participants and limited follow-up period do not allow definitive conclusions about the risks associated with gene editing or the long-term safety of this approach.


What Are the Next Challenges for CTX310?


Despite the early results, several questions require further investigation. These include the durability of gene editing, the persistence of its effects on lipid metabolism, the potential occurrence of unintended genetic changes (off-target edits), and delayed effects of the intervention. Responses will also need to be assessed in larger populations with different clinical and metabolic characteristics, along with the strategy’s impact on clinical outcomes such as pancreatitis and cardiovascular events.


The results presented at the AHA meeting relate to a specific phase 1b cohort involving participants with severe hypertriglyceridemia. They should not be confused with earlier phase 1a results published in 2025 in the New England Journal of Medicine, which evaluated different doses of CTX310 in adults with various lipid abnormalities. Clinical development of the therapy remains ongoing, with other phase 1b cohorts being investigated in different populations with lipid metabolism disorders.


The company also reported that the U.S. Food and Drug Administration (FDA) granted CTX310 Regenerative Medicine Advanced Therapy (RMAT) designation for its development in patients with severe hypertriglyceridemia and elevated LDL-C levels. This designation provides regulatory support mechanisms for clinical development, but it does not constitute marketing approval or definitive evidence of efficacy.


In Vivo Gene Editing and New Therapeutic Possibilities


The CTX310 results expand the scope of CRISPR-Cas9 research beyond the genetic diseases traditionally associated with gene therapy. Using gene editing to modify targets involved in lipid metabolism demonstrates the technology’s potential for investigating new approaches to metabolic and cardiovascular diseases.


The ability to administer gene-editing components directly into the body and modify a specific molecular target represents a different strategy from conventional therapies, which generally rely on ongoing administration or repeated pharmacological interventions.


Although further studies are needed to establish safety, efficacy, and the durability of its effects, CTX310 represents a relevant example of progress in in vivo gene-editing therapies and their potential applications across different areas of medicine.


Following upcoming clinical results will be essential to understanding the potential of this approach and assessing whether gene editing of targets involved in lipid metabolism could become a therapeutic option for patients with severe lipid abnormalities.


References


  1. CRISPR THERAPEUTICS. CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026. 9 nov. 2026. Acessar comunicado oficial.

  2. LAFFIN, L. J. et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. New England Journal of Medicine, v. 393, p. 2119–2130, 2025. DOI: 10.1056/NEJMoa2511778. Acessar artigo científico.

  3. SYLVERS-DAVIE, K. L.; DAVIES, B. S. J. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. American Journal of Physiology-Endocrinology and Metabolism, v. 321, n. 4, p. E493–E508, 2021. DOI: 10.1152/ajpendo.00195.2021. Acessar artigo científico.


CRISPR-Cas9: Experimental CTX310 Therapy Reduces Triglycerides in a Phase 1b Clinical Trial.
CRISPR-Cas9: Experimental CTX310 Therapy Reduces Triglycerides in a Phase 1b Clinical Trial.

 
 
 

Comments


bottom of page